Cargando…
EpCAM Immunotherapy versus Specific Targeted Delivery of Drugs
The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans...
Autores principales: | Macdonald, Joanna, Henri, Justin, Roy, Kislay, Hays, Emma, Bauer, Michelle, Veedu, Rakesh Naduvile, Pouliot, Normand, Shigdar, Sarah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5789369/ https://www.ncbi.nlm.nih.gov/pubmed/29329202 http://dx.doi.org/10.3390/cancers10010019 |
Ejemplares similares
-
Bifunctional Aptamer–Doxorubicin Conjugate Crosses the Blood–Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells
por: Macdonald, Joanna, et al.
Publicado: (2020) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014) -
Targeting EpCAM (CD326) for immunotherapy in hepatoblastoma
por: Armeanu-Ebinger, Sorin, et al.
Publicado: (2013) -
EpCAM aptamer mediated cancer cell specific delivery of EpCAM siRNA using polymeric nanocomplex
por: Subramanian, Nithya, et al.
Publicado: (2015)